|
|
¡á ½ÄÇ°ÀǾàÇ°¾ÈÀüó ¼Ò½Ä |
ÀÇ°ß
Á¶È¸
|
¡¸»ý¹°ÀǾàÇ° Á¦Á¶¹æ¹ý º¯°æ¿¡ µû¸¥ ºñ±³µ¿µî¼º Æò°¡ °¡À̵å¶óÀΡ¹°³Á¤(¾È) ÀÇ°ßÁ¶È¸(~12/14±îÁö) |
[ÁÖ¿ä»çÇ×]
• Á¦¸ñ : »ý¹°ÀǾàÇ°ÀÇ Á¦Á¶¹æ¹ý º¯°æ¿¡ ´Ù¸¥ ºñ±³µ¿µî¼º Æò°¡ °¡À̵å¶óÀÎ °³Á¤(¾È)
• ÁÖ¿ä³»¿ë : ¹é½Å, À¯ÀüÀÚÀçÁ¶ÇÕÀǾàÇ° Á¦Á¶¹æ¹ý º¯°æÀÇ Áß¿äµµ¿¡ µû¶ó Áß¿ä/º¸Åë/°æ¹Ì·Î ºÐ·ù ¹× Á¶°Ç,±Ù°ÅÀÚ·á ±â¼ú
• ÀÇ°ßÁ¶È¸ ±âÇÑ : ~ '17.12.14(¸ñ) ±îÁö
• Á¦Ãâó : °ËÅäÀÇ°ß¼ info@kobia.kr·Î ¼ÛºÎ |
[1] »ý¹°ÀǾàÇ°ÀÇ Á¦Á¶¹æ¹ý º¯°æ¿¡ µû¸¥ ºñ±³µ¿µî¼º Æò°¡ °¡À̵å¶óÀÎ °³Á¤(¾È)? È®ÀÎ
[2] °ËÅäÀÇ°ß¼(¾ç½Ä) È®ÀÎ
|
|
°ø¹«¿ø
Áöħ¼ |
WHO ±¹Á¦±³À°ÈƷü¾ÅÍ ±¹°¡ÃâÇϽÂÀÎ ½ÃÇè°ËÁ¤ ±¹Á¦±³À° ¿î¿µÀýÂ÷
|
¼¼°èº¸°Ç±â±¸(WHO)¿¡¼ ¹é½Å Ç°Áú°ü¸® ±¹°¡ÃâÇϽÂÀÎ/½ÃÇè°ËÁ¤ ºÐ¾ß¿¡ ±¹Á¦±³À°ÈƷü¾ÅÍ·Î ÁöÁ¤µÈ ¹é½Å°ËÁ¤°ú¿¡¼ °ü·Ã ±¹Á¦±³À° Çà»ç ¼öÇàÇÔ¿¡ ÀÖ¾î Á¶´Þ°è¾àºÎÅÍ ±³À°¼öÇà, WHO º»ºÎ¿¡ °á°úº¸°í µîÀÇ ÀÏ·ÃÀÇ ¾÷¹« ¼öÇà ÀýÂ÷¸¦ ¹®¼ÈÇÔ
¢º Áöħ¼ È®ÀÎ
|
|
¹ßÇ¥
ÀÚ·á |
ÀÓ»ó½ÃÇè °ü·Ã ¹ý·É °³Á¤»çÇ× Á¤Ã¥¼³¸íȸ ÀÚ·á °øÀ¯ |
±¹³» Á¦¾à»ç, ÀÓ»ó½ÃÇè½Ç½Ã±â°ü µîÀ» ´ë»óÀ¸·Î 11¿ù 27ÀÏ ÄÚ¿¢½º¿¡¼ °³ÃÖÇÑ ¡®ÀÓ»ó °ü·Ã ¹ý·É °³Á¤ »çÇ× Á¤Ã¥ ¼³¸íȸ¡¯ÀÇ ¹ßÇ¥ÀÚ·áÀÌ´Ù. ÇØ´ç ¼³¸íȸ´Â Áö³ 10¿ù °³Á¤µÈ ¡®¾à»ç¹ý¡¯°ú ÇâÈÄ °³Á¤µÉ ¡®ÀǾàÇ° µîÀÇ ¾ÈÀü¿¡ °üÇÑ ±ÔÄ¢¡¯ÀÇ °³Á¤ÃëÁö¿Í ³»¿ëÀ» ¾È³»ÇØ »õ·Î µµÀԵǴ ÀÓ»ó½ÃÇè °ü·Ã Á¦µµÀÇ ¿øÈ°ÇÑ ½ÃÇàÀ» À§ÇØ ¸¶·ÃµÆ´Ù. ÁÖ¿ä ³»¿ëÀº ¡ãÀÓ»ó½ÃÇè ¹× »ý¹°ÇÐÀûµ¿µî¼º½ÃÇè ÅëÇÕ°ü¸® ¡ãÀÓ»ó½ÃÇè°ËüºÐ¼®±â°ü ÁöÁ¤Á¦µµ µµÀÔ ¡ãÂü¿©ÀÚ ¸ðÁý°ø°í ½Ã Àǹ«±âÀç»çÇ× ½Å¼³ µî ½ÃÇè´ë»óÀÚ º¸È£ Á¤Ã¥ ¡ãÄ¡·á¸ñÀû »ç¿ë½ÂÀÎ Á¦µµ°³¼± »çÇ× µîÀÌ´Ù.
¢º ¹ßÇ¥ÀÚ·á È®ÀÎ
|
|
|
|
|
¡á ±¹³» ÀÓ»ó ÇöȲ |
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
½ÃÇèÁ¦¸ñ |
´Ü°è |
Çѱ¹
¿¥¿¡½ºµð(À¯) |
20171204 |
ÀüÀ̼º ºñ¼Ò¼¼Æ÷ Æó¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î 1Â÷ Ä¡·á·Î¼ÀÇ Pembrolizumab (MK-3475) + Epacadostat (INCB024360) ¡¾ ¹é±Ý ±â¹Ý ÈÇпä¹ýÀÇ º´¿ë¿ä¹ýÀ» Pembrolizumab + ¹é±Ý ±â¹Ý ÈÇпä¹ý + À§¾à°ú ºñ±³ Æò°¡ÇÏ´Â ¹«ÀÛÀ§¹èÁ¤ Á¦3»ó ÀÓ»ó½ÃÇè |
3»ó |
¿¡ÆÄÄ«µµ½ºÅÂÆ® 25mg, 100mg |
(ÁÖ)Çѱ¹
¾á¼¾ |
20171201 |
Àç¹ß¼º ¶Ç´Â ºÒÀÀ¼º ´Ù¹ß¼º °ñ¼öÁ¾ÀÌ ÀÖ´Â ½ÃÇè´ë»óÀÚ¿¡¼ DaratumumabÀÇ ÇÇÇÏ ´ë Á¤¸Æ ³» Åõ¿©ÀÇ Á¦3»ó ¹«ÀÛÀ§ ¹èÁ¤, ´Ù±â°ü ÀÓ»ó½ÃÇè |
3»ó |
Daratumumab
(JNJ-54767414) |
Çѱ¹
¿¥¿¡½ºµð(À¯) |
20171201 |
ÁøÇ༺ °íÇüÁ¾¾ç ȯÀÚ¸¦ ´ë»óÀ¸·Î Pembrolizumab (MK-3475) +/- ±âŸ ¿ä¹ýÁ¦¿ÍÀÇ º´¿ë¿ä¹ýÀ¸·Î Åõ¿©ÇÑ MK-7162¸¦ Æò°¡ÇÏ´Â Á¦1b»ó ¶óº§-°ø°³ ÀÓ»ó½ÃÇè |
1b»ó |
MK-7162
Pembrolizumab |
|
|
¡á ÇØ¿ÜÀǾàÇ° Çã°¡ÇöȲ |
¹Ì±¹ |
|
|
|
Drug name |
Active Ingredients |
Submission Classification |
Company |
Approval date |
IMPOYZ
NDA #209483 |
CLOBETASOL PROPIONATE |
½ÅÁ¦Çü ¶Ç´Â ½ÅÁ¦Á¶¿ø |
PROMIUS PHARMA LLC |
11/28/2017 |
CLENPIQ
NDA #209589 |
SODIUM PICOSULFATE;MAGNESIUM OXIDE;ANHYDROUS CITRIC ACID |
½Å¿ë·® |
FERRING PHARMS INC |
11/28/2017 |
SUBLOCADE
NDA #209819 |
BUPRENORPHINE |
½Å¿ë·® |
INDIVIOR INC |
11/30/2017 |
OGIVRI
BLA #761074 |
TRASTUZUMAB-DKST |
- |
MYLAN GMBH |
12/01/2017 |
|
|
À¯·´ |
|
|
|
Name |
Active Substance |
Therapeutic Area |
Date of Authorisation / Refusal |
Tremfya |
guselkumab |
Psoriasis |
10/11/2017 |
Tookad |
padeliporfin di-potassium |
Prostatic Neoplasms |
10/11/2017 |
Adlumiz |
anamorelin hydrochloride |
Anorexia
Cachexia
Carcinoma, Non-Small-Cell Lung |
16/11/2017 |
|
|
¡á ÇؿܹÙÀÌ¿ÀÀǾàÇ° ÀÓ»óÇöȲ |
¹Ì±¹ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor |
Phases |
NCT03360890 |
Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors |
Thyroid Cancer
Salivary Gland Cancer |
Drug: Pembrolizumab
Drug: Docetaxel |
University of Chicago |
Phase 2 |
NCT03359356 |
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) |
Alopecia Areata |
Drug: Dupilumab
Drug: Placebos |
Icahn School of Medicine at
Mount Sinai |
Phase 2 |
NCT03359239 |
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer |
Urothelial/Bladder Cancer, Nos |
Drug: Atezolizumab
Biological: PGV001
Drug: Poly ICLC
Drug: Normal saline |
Matthew Galsky
Genentech, Inc.
Icahn School of Medicine at
Mount Sinai |
Phase 1 |
NCT03358719 |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
Acute Myeloid Leukemia
Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia |
Biological:
DEC-205/NY-ESO-1 Fusion Protein
CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Poly ICLC |
Roswell Park Cancer Institute
National Cancer Institute (NCI) |
Phase 1 |
NCT03361228 |
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors |
Advanced or Metastatic Solid Tumors |
Drug: INCB001158
Drug: Epacadostat
Drug: Pembrolizumab |
Incyte
Corporation |
Phase 1
Phase 2 |
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion
Drug: Ustekinumab SC Injection
Drug:
Midazolam 2 mg.. |
Janssen Research & Development, LLC |
Phase 1 |
NCT03357952 |
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: Daratumumab
Drug: JNJ-63723283 |
Janssen Research & Development, LLC |
Phase 1 |
|
|
À¯·´ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor |
Phases |
ºñ°í |
NCT03361228 |
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors |
Advanced or Metastatic Solid Tumors |
Drug: INCB001158
Drug: Epacadostat
Drug: Pembrolizumab |
Incyte Corporation |
Phase 1
Phase 2 |
ÇÁ¶û½º |
NCT03360734 |
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors |
Solid Tumor, Adult |
Biological: Gatipotuzumab and Tomuzotuximab |
Glycotope GmbH |
Phase 1 |
µ¶ÀÏ |
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion
Drug: Ustekinumab SC Injection
Drug: Midazolam 2 mg... |
Janssen Research & Development, LLC |
Phase 1 |
µ¶ÀÏ |
NCT03357952 |
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: Daratumumab
Drug: JNJ-63723283 |
Janssen Research & Development, LLC |
Phase 1 |
µ¶ÀÏ |
|
|
Áß±¹ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor/
Collaborators |
Phases |
NCT03360630 |
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC |
Lung Cancer
Neoplasms |
Biological: Anti-PD-1 plus DC-CIK
Biological: Anti-PD-1 alone |
Capital Medical University
Duke University
Geneplus-Beijing Co. Ltd. |
Phase 1
Phase 2 |
NCT03359018 |
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma |
Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity |
Drug: Apatinib
Drug: Camrelizumab |
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd. |
Phase 2 |
|
|
¡á ¾÷°è ¼Ò½Ä |
»ï¼º¹ÙÀÌ¿À·ÎÁ÷½º, ¼¼°è ÃÖ´ë ±Ô¸ð ¹ÙÀÌ¿ÀÀǾàÇ° Á¦3°øÀå ÁØ°ø |
|
-¼¿ï ¿ùµåÄÅ°æ±âÀå µÎ ¹è, 18¸¸§¤ »ý»ê ±Ô¸ð
-1, 2°øÀå°ú ´õÇÏ¸é »ý»ê ±Ô¸ð 36¸¸§¤·Î ¼¼°è ÃÖ´ë
»ï¼º¹ÙÀÌ¿À·ÎÁ÷½º°¡ ´ÜÀÏ ¹ÙÀÌ¿ÀÀǾàÇ° »ý»ê °øÀå ±Ô¸ð·Î´Â ¼¼°è ÃÖ´ë ±Ô¸ð¿¡ ÇØ´çÇÏ´Â Á¦3°øÀåÀ» ÁØ°øÇß´Ù. ¹ÙÀÌ¿ÀÀǾàÇ° À§Å¹»ý»ê(CMO) ºÐ¾ß¿¡ ÀÖ¾î ¼¼°è 1À§·Î µµ¾àÇÏ´Â °è±â°¡ µÉ °ÍÀ¸·Î ±â´ëµÈ´Ù.... (±â»ç Àü¹®)
|
|
¡á Çùȸ ¼Ò½Ä |
|
|
|
|
|
|
|
|
|
|
|
| | ¸ÞÀÏÀ» ¿øÇÏÁö ¾ÊÀ¸½Ç °æ¿ì [¼ö½Å°ÅºÎ]¸¦ Ŭ¸¯ÇØ ÁÖ¼¼¿ä. If you don't want this type of information or e-mail, please [click here]. |
|
|
|
|
|